Vertex Pharmaceuticals Incorporated has announced new data from multiple studies demonstrating positive clinical and quality of life benefits associated with the cystic fibrosis treatment ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor). The data, which was presented at the 48th European Cystic Fibrosis Conference held from June 4-7, 2025, in Milan, Italy, suggests that ALYFTREK is linked to improved health-related quality of life outcomes compared to TRIKAFTA®. The studies include both randomized, controlled and open-label trials. The findings indicate that reductions in sweat chloride levels achieved through treatment with CFTR modulators like ALYFTREK are correlated with better patient outcomes, including enhanced CF symptoms and general functioning in children aged 6-11 years. ALYFTREK is approved in the United States and United Kingdom, and is under review in other regions including the EU, Canada, Australia, New Zealand, and Switzerland.